Trevi Therapeutics Inc (TRVI) — Cash Flow-to-Debt Ratio
Trevi Therapeutics Inc (TRVI) has a Cash Flow-to-Debt Ratio of -2.23x as of March 2026, meaning its operating cash flow of $-16.69 Million could theoretically repay -2% of its total liabilities ($7.48 Million) in one year. Explore TRVI long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Trevi Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Trevi Therapeutics Inc across 10 annual periods. Also explore TRVI total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Trevi Therapeutics Inc (2016–2025)
Year-by-year debt coverage analysis for Trevi Therapeutics Inc. For market capitalisation and broader financial context, see Trevi Therapeutics Inc (TRVI) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.13x | $-42.09 Million | $10.20 Million | ▼ -21.5% |
| 2024 | -3.40x | $-38.26 Million | $11.26 Million | ▲ +26.5% |
| 2023 | -4.63x | $-31.71 Million | $6.86 Million | ▼ -155.4% |
| 2022 | -1.81x | $-28.18 Million | $15.56 Million | ▼ -33.9% |
| 2021 | -1.35x | $-28.95 Million | $21.40 Million | ▲ +7.4% |
| 2020 | -1.46x | $-29.00 Million | $19.85 Million | ▲ +65.5% |
| 2019 | -4.23x | $-23.09 Million | $5.46 Million | ▲ +26.4% |
| 2018 | -5.75x | $-18.29 Million | $3.18 Million | ▼ -437.0% |
| 2017 | -1.07x | $-7.97 Million | $7.45 Million | ▼ -146.9% |
| 2016 | -0.43x | $-11.19 Million | $25.82 Million | — |